An AMPK paradox in pulmonary arterial hypertension


Adenosine monophosphate-activated protein kinase (AMPK) is a heterotrimeric serine-threonine kinase important as a metabolic sensor for intracellular ATP levels and plays a key role in regulating cell survival and proliferation, particularly when cells are exposed to hypoxia. AMPK is critical for lung function, and abnormal AMPK signaling participates in many lung diseases. Recent studies suggest that both inhibition and activation of AMPK are preventive for the development of pulmonary arterial hypertension (PAH). However, the molecular mechanisms by which inhibition or activation of AMPK affects pulmonary hypertension (PH) appear to be distinct. Inhibition of AMPK by compound C blocks hypoxia-induced autophagy and induces apoptosis in pulmonary artery smooth muscle cells, leading to prevention of PAH; activation of AMPK by metformin attenuates the PH phenotype induced by hypoxia by regulating endothelial cell function. These seemingly opposing data on the function of AMPK in PH can be partly explained by off-target and compartment-specific effects of AMPK inhibitors and activators and the differentiated expression of AMPK in various cell types and subcellular locations. To elucidate the specific roles of AMPK in the pathogenesis of PAH, it is important to study the role of AMPK in a tissue specific manner combining genetic and biochemical approaches.


Share and Cite:

Sun, M. and Zhou, G. (2013) An AMPK paradox in pulmonary arterial hypertension. Journal of Biomedical Science and Engineering, 6, 1085-1089. doi: 10.4236/jbise.2013.611136.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Humbert, M., Sitbon, O. and Simonneau, G. (2004) Treatment of pulmonary arterial hypertension. New England Journal of Medicine, 351, 1425-1436.
[2] McLaughlin, V.V., Archer, S.L., Badesch, D.B., Barst, R.J., Farber, H.W., Lindner, J.R., et al. (2009) ACCF/ AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation, 119, 2250-2294.
[3] Durmowicz, A.G. and Stenmark, K.R. (1999) Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatrics in Review/American Academy of Pediatrics, b, e91-e102.
[4] Stenmark, K.R., Fagan, K.A. and Frid, M.G. (2006) Hypoxia-induced pulmonary vascular remodeling: Cellular and molecular mechanisms. Circulation Research, 99, 675-691.
[5] Evans, A.M., Hardie, D.G., Peers, C., Wyatt, C.N., Viollet, B., Kumar, P., et al. (2009) Ion channel regulation by AMPK: The route of hypoxia-response coupling in the carotid body and pulmonary artery. Annals of the New York Academy of Sciences, 1177, 89-100.
[6] Horman, S., Morel, N., Vertommen, D., Hussain, N., Neumann, D., Beauloye, C., et al. (2008) AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase. The Journal of BioLogical Chemistry, 283, 18505-18512.
[7] Hattori, Y., Akimoto, K., Nishikimi, T., Matsuoka, H. and Kasai, K. (2006) Activation of AMP-activated protein kinase enhances angiotensin ii-induced proliferation in cardiac fibroblasts. Hypertension, 47, 265-270.
[8] Park, H.U., Suy, S., Danner, M., Dailey, V., Zhang, Y., Li, H., et al. (2009) AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Molecular cancer therapeutics, 8, 733-741.
[9] Mishra, R., Cool, B.L., Laderoute, K.R., Foretz, N., Viollet, B. and Simonson, M.S. (2008) AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. The Journal of Biological Chemistry, 283, 10461-10469.
[10] Creighton, J., Jian, M., Sayner, S., Alexeyev, M. and Insel, P.A. (2011) Adenosine monophosphate-activated kinase alpha1 promotes endothelial barrier repair. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 25, 3356-3365.
[11] Evans, A.M., Mustard, K.J.W., Wyatt, C.N., Dipp, M., Kinnear, N.P. and Hardie, D.G. (2006) Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to pulmonary artery constriction? Advances in experimental medicine and biology, 580, 147-154.
[12] Dada, L., Gonzalez, A.R., Urich, D., Soberanes, S., Manghi, T.S., Chiarella, S.E., et al. (2012) Alcohol worsens acute lung injury by inhibiting alveolar sodium transport through the adenosine A1 receptor. PLoS ONE [Electronic Resource], 7, Article ID: e30448.
[13] Gusarova, G.A., Dada, L.A., Kelly, A.M., Brodie, C., Witters, L.A., Chandel N.S. and Sznajder, J.I. (2009) Alpha1-AMP-activated protein kinase regulates hypoxiainduced Na,K-ATPase endocytosis via direct phosphorylation of protein kinase C zeta. Molecular and cellular biology, 29, 3455-3464.
[14] Gusarova, G.A., Trejo, H.E., Dada, L.A., Briva, A., Welch, L.C., Hamanaka, R.B., et al. (2011) Hypoxia leads to Na,K-ATPase downregulation via Ca(2+) release-activated Ca(2+) channels and AMPK activation. Molecular and cellular biology, 31, 3546-3556.
[15] Mungai, P.T., Waypa, G.B., Jairaman, A., Prakriya, M., Dokic, D., Ball, M.K., et al. (2011) Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Molecular and cellular biology, 31, 3531-3545.
[16] Vadász, I., Dada, L.A., Briva, A., Trejo, H.E., Welch, L.C., Chen, J., et al. (2008) AMP-activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na,K-ATPase endocytosis. Journal of Clinical Investigation, 118, 752-762.
[17] Ibe, J.C., Zhou, Q., Chen, T., Tang, H., Yuan, J.X., Raj, J.U., et al. (2013) AMPK is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, in Press.
[18] Agard, C., Rolli-Derkinderen, M., Dumas-de-La-Roque, E., Rio, M., Sagan, C., Savineau, J.P., et al. (2009) Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. British journal of Pharmacology, 158, 1285-1294.
[19] Borst, S.E. and Snellen, H.G. (2001) Metformin, but not exercise training, increases insulin responsiveness in skeletal muscle of Sprague-Dawley rats. Life Sciences, 69, 1497-1507.
[20] Hundal, R.S., Krssak, M., Dufour, S., Laurent, D., Lebon, V., Chandramouli, V., et al. (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 49, 2063-2069.
[21] McAlister, F.A., Eurich, D.T., Majumdar, S.R. and Johnson, J.A. (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. European Journal of Heart Failure, 10, 703-708.
[22] Davis, B.J., Xie, Z., Viollet, B. and Zou, M.H. (2006) Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes, 55, 496-505.
[23] Fagan, K.A., Oka, M., Bauer, N.R., Gebb, S.A., Ivy, D.D., Morris, K.G., et al. (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. American journal of physiology Lung cellular and molecular physiology, 287, L656-L664.
[24] Morrow, V.A., Foufelle, F., Connell, J.M.C., Petrie, J.R., Gould, G.W. and Salt, I.P. (2003) Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. The Journal of Biological Chemistry, 278, 31629-31639.
[25] Creighton, J. (2011) Targeting therapeutic effects: Subcellular location matters. Focus on “Pharmacological AMPkinase activators have compartment-specific effects on cell physiology”. American Journal of Physiology Cell Physiology, 301, C1293-C1295.
[26] Kodiha, M., Ho-Wo-Cheong, D. and Stochaj, U. (2011) Pharmacological AMP-kinase activators have compartment-specific effects on cell physiology. American JourNal of Physiology Cell Physiology, 301, C1307-C1315.
[27] Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., et al. (2010) AMPK inhibition in health and disease. Critical Reviews in Biochemistry and MoLecular Biology, 45, 276-295.
[28] Viollet, B., Athea, Y., Mounier, R., Guigas, B., Zarrinpashneh, E., Horman, S., et al. (2009) AMPK: Lessons from transgenic and knockout animals. Frontiers in BioScience: A Journal and Virtual Library, 14, 19-44.
[29] Chhipa, R.R., Wu, Y., Mohler, J.L. and Ip, C. (2010) Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cellular Signalling, 22, 1554-1561.
[30] Igata, M., Motoshima, H., Tsuruzoe, K., Kojima, K., Matsumura, T., Kondo, T., et al. (2005) Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circulation Research, 97, 837-844.
[31] Nagata, D., Takeda, R., Sata, M., Satonaka, H., Suzuki, E., Nagano, T. and Hirata, Y. (2004) AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation, 110, 444-451.
[32] Vucicevic, L., Misirkic, M., Janjetovic, K., Harhaji-Trajkovic, L., Prica, M., Stevanovic, D., et al. (2009) AMPactivated protein kinase-dependent and independent mechanisms underlying in vitro antiglioma action of compound C. Biochemical Pharmacology, 77, 1684-1693.
[33] Krymskaya, V.P., Snow, J., Cesarone, G., Khavin, I., Goncharov, D.A., Lim, P.N., et al. (2011) mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 25, 1922-1933.
[34] Evans, A.M. (2006) AMP-activated protein kinase underpins hypoxic pulmonary vasoconstriction and carotid body excitation by hypoxia in mammals. Experimental physiology, 91, 821-827.
[35] Robertson, T.P., Mustard, K.J.W., Lewis, T.H., Clark, J.H., Wyatt, C.N., Blanco, E.A., et al. (2008) AMP-activated protein kinase and hypoxic pulmonary vasoconstriction. European Journal of Pharmacology, 595, 39-43.
[36] Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-3586.
[37] Zhuang, Y. and Miskimins, W.K. (2008) Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of Molecular Signaling, 3, 18.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.